Q4 2017 EPS Estimates for G1 THERAPEUTICS (GTHX) Lifted by Wedbush

G1 THERAPEUTICS (NASDAQ:GTHX) – Wedbush upped their Q4 2017 earnings per share (EPS) estimates for G1 THERAPEUTICS in a research report issued on Wednesday. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.58) per share for the quarter, up from their previous forecast of ($0.61). Wedbush also issued estimates for G1 THERAPEUTICS’s Q1 2018 earnings at ($0.50) EPS, Q2 2018 earnings at ($0.53) EPS, Q3 2018 earnings at ($0.56) EPS, Q4 2018 earnings at ($0.59) EPS, FY2018 earnings at ($2.18) EPS, FY2019 earnings at ($2.34) EPS, FY2020 earnings at ($2.10) EPS and FY2021 earnings at ($1.31) EPS.

Several other analysts have also weighed in on GTHX. Cowen and Company reissued a “buy” rating on shares of G1 THERAPEUTICS in a report on Wednesday, August 9th. Zacks Investment Research lowered G1 THERAPEUTICS from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $29.75.

TRADEMARK VIOLATION WARNING: “Q4 2017 EPS Estimates for G1 THERAPEUTICS (GTHX) Lifted by Wedbush” was first published by Markets Daily and is owned by of Markets Daily. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.themarketsdaily.com/2017/11/14/q4-2017-eps-estimates-for-g1-therapeutics-gthx-lifted-by-wedbush.html.

Shares of G1 THERAPEUTICS (NASDAQ GTHX) opened at $19.71 on Monday. G1 THERAPEUTICS has a fifty-two week low of $12.04 and a fifty-two week high of $28.67.

Institutional investors have recently bought and sold shares of the stock. American International Group Inc. bought a new position in shares of G1 THERAPEUTICS during the 3rd quarter worth approximately $130,000. California State Teachers Retirement System bought a new position in shares of G1 THERAPEUTICS during the 3rd quarter worth approximately $319,000. Schwab Charles Investment Management Inc. bought a new position in shares of G1 THERAPEUTICS during the 3rd quarter worth approximately $364,000. Alps Advisors Inc. bought a new position in shares of G1 THERAPEUTICS during the 2nd quarter worth approximately $444,000. Finally, Bank of New York Mellon Corp bought a new position in shares of G1 THERAPEUTICS during the 3rd quarter worth approximately $568,000. Institutional investors and hedge funds own 35.28% of the company’s stock.

About G1 THERAPEUTICS

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Earnings History and Estimates for G1 THERAPEUTICS (NASDAQ:GTHX)

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply